ArticleVaccines2020
Intratumoral Combinatorial Administration of CD1c (BDCA-1)
Article in Vaccines, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- ERK1/2 Phosphorylation Predicts Survival in Recurrent Glioblastoma Following Intracerebral and Adjuvant PD-1/CTLA-4 Immunotherapy: A REMARK-guided Analysis.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Pooled it
- A randomized phase II clinical trial of stereotactic body radiation therapy (SBRT) and systemic pembrolizumab with or without intratumoral avelumab/ipilimumab plus CD1c (BDCA-1)Cancer immunology, immunotherapy : CII · 2024Trial
- Review
- Impact of tumor localization on antitumor immunity with conditionally activated CTLA-4 blockade.Journal for immunotherapy of cancer · 2025Article
- Dendritic cells as orchestrators of anticancer immunity and immunotherapy.Nature reviews. Clinical oncology · 2024Review
- Intratumoral administration of the immunologic adjuvant AS01Journal for immunotherapy of cancer · 2024Article
- Intratumoral delivery of immunotherapy to treat breast cancer: current development in clinical and preclinical studies.Frontiers in immunology · 2024Review
- Dendritic cell subsets and implications for cancer immunotherapy.Frontiers in immunology · 2024Review
- Dendritic Cell Subsets in Melanoma: Pathophysiology, Clinical Prognosis and Therapeutic Exploitation.Cancers · 2023Review
- Intratumoral administration of CD1c (BDCA-1)Journal for immunotherapy of cancer · 2022Article
- Oncolytic Herpes Simplex Virus Type 1 Induces Immunogenic Cell Death Resulting in Maturation of BDCA-1International journal of molecular sciences · 2022Article
- Review
- Article
- Trial watch: Dendritic cell (DC)-based immunotherapy for cancer.Oncoimmunology · 2022Article
- Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 3rd-5th, 2020, Italy).Journal of translational medicine · 2021Article
- Intracerebral administration of CTLA-4 and PD-1 immune checkpoint blocking monoclonal antibodies in patients with recurrent glioblastoma: a phase I clinical trial.Journal for immunotherapy of cancer · 2021Article
- Tissue Multiplex Analyte Detection in Anatomic Pathology - Pathways to Clinical Implementation.Frontiers in molecular biosciences · 2021Review
- Trial watch: intratumoral immunotherapy.Oncoimmunology · 2021Review
- The clinical application of cancer immunotherapy based on naturally circulating dendritic cells.Journal for immunotherapy of cancer · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
Intratumoral (IT) myeloid dendritic cells (myDCs) play a pivotal role in re-licensing antitumor cytotoxic T lymphocytes. IT injection of the IgG
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.